Kodiak Sciences (NASDAQ:KOD) Earns Buy Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Kodiak Sciences (NASDAQ:KOD) in a research note issued to investors on Monday morning, MarketBeat reports. The firm issued a buy rating and a $15.00 target price on the stock.

KOD has been the topic of several other research reports. JPMorgan Chase & Co. upgraded Kodiak Sciences from an “underweight” rating to a “neutral” rating and set a $15.00 price objective on the stock in a research note on Thursday, August 14th. Barclays upped their price objective on Kodiak Sciences from $4.00 to $7.00 and gave the company an “underweight” rating in a research note on Thursday, August 14th. Finally, HC Wainwright upped their price objective on Kodiak Sciences from $3.00 to $5.00 and gave the company a “neutral” rating in a research note on Monday, August 18th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Kodiak Sciences has a consensus rating of “Hold” and a consensus price target of $10.50.

Kodiak Sciences Trading Up 12.9%

Kodiak Sciences stock opened at $15.49 on Monday. Kodiak Sciences has a 12 month low of $1.92 and a 12 month high of $16.30. The business’s 50 day simple moving average is $8.99 and its 200 day simple moving average is $5.43. The company has a market cap of $818.18 million, a price-to-earnings ratio of -4.08 and a beta of 2.45.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.02). As a group, equities research analysts forecast that Kodiak Sciences will post -3.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kodiak Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC raised its holdings in Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after acquiring an additional 5,815 shares during the period. US Bancorp DE raised its holdings in Kodiak Sciences by 131.7% during the 1st quarter. US Bancorp DE now owns 9,282 shares of the company’s stock valued at $26,000 after acquiring an additional 5,276 shares during the period. Vontobel Holding Ltd. bought a new stake in Kodiak Sciences during the 1st quarter valued at $28,000. Public Employees Retirement System of Ohio raised its holdings in Kodiak Sciences by 183.9% during the 4th quarter. Public Employees Retirement System of Ohio now owns 14,759 shares of the company’s stock valued at $147,000 after acquiring an additional 9,560 shares during the period. Finally, Vanguard Personalized Indexing Management LLC increased its holdings in shares of Kodiak Sciences by 21.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company’s stock worth $56,000 after purchasing an additional 2,691 shares during the period. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.